Sector News

Boehringer Ingelheim will hire 400

December 24, 2015
Life sciences

Germany’s Boehringer Ingelheim has been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its revenues. After doing deals to bolster its top line, it will now spend some money on manufacturing in hopes of riding the biopharma boom to greater heights, adding about 400 jobs in the process.

The company said Tuesday it will it build a commercial-scale biopharmaceutical production facility in Vienna, Austria, to produce active ingredients using cell cultures. It said it will fill in the details later but that it will spend roughly €500 million ($550 million) on the plant and take on up to 400 employees when it opens in 2021.

“This is a decision for Europe as a pharma location,” Boehringer Chairman Andreas Barner, said in a statement. Vienna was picked, Barner explained, after sizing up other international locations and considering the “research environment at potential sites.”

Boehringer’s key biopharma production is done in Biberach, Germany, but the company needs extra capacity for its pipeline and decided to build in a new location to spread the risk. It also expects to do more production for other companies. Sanofi this year selected Boehringer to handle some of its monoclonal antibodies (mAbs) manufacturing for drugs the French drugmaker has been working on with U.S. partner Regeneron.

Last week Boehringer and Sanofi announced negotiations around entirely different parts of their business. Boehringer intends to trade its consumer health business and pay the French drugmaker €4.7 billion for its Merial animal health unit. Each company expects the swap to boost its fortunes as they both struggle with soft spots in their businesses.

Germany’s second largest drugmaker has been dealing with patent losses and pricing pressures that have led it to lay off workers and unload assets. It sold its U.S. generics operation, Roxane Labs to Jordan’s Hikma Pharmaceuticals this year for $2.65 billion, saying it needed to focus on drug development and branded drug sales.

It has had some notable success in recent weeks with its drug development. The FDA approved the company’s Praxbind, a reversal agent for patients taking the drugmaker’s clot-fighter Pradaxa. It won an FDA breakthrough therapy designation for a drug candidate that demonstrated early-stage promise for T790M-positive cases of non-small cell lung cancer. The FDA last week also approved the biosimilar of Sanofi’s massively popular Lantus insulin that Boehringer developed with partner Eli Lilly.

To shepherd it through the next phase of its business, the company has picked a new, younger leader. It recently announced that Hubertus von Baumbach, a great-grandson of founder Albert Boehringer, would take over when Barner steps out of the the top role next year.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”